Strengthening Clinical CRO Business in China


Tokyo – April 1, 2020 – CMIC group is a provider of high-quality solutions for the healthcare industry and the first company to provide CRO (contract research organization) services in Japan. We are pleased to announce today that the company will reorganize its clinical CRO business in China and integrate its wholly-owned subsidiaries CMIC (Beijing) Co., Ltd. (hereinafter referred to as “CB”) and CMIC (Beijing) Pharmaceutical Services Co., Ltd. (hereinafter referred to as “CPS”) on April 1.

Today, CMIC provides service covered by 14 companies in broader Asia Pacific countries including Japan and Asia (Greater China, South Korea, Southeast Asia and Australia), with position as the largest clinical CRO in Japan. “Strengthening competitiveness and promoting globalization” is one key growth strategy in CMIC’s mid-term plan.

Considering the fast growing of pharmaceutical development and medical technology advancement in China, this merger aims to improve the efficiency of business strategies and operations execution and further strengthening our clinical CRO services in China under one consolidated entity.

“Through this merger, CMIC group is able to leverage combined know-how and accumulated experiences enabling the company to provide higher quality, better efficiency, and seamless service solutions in China.” said Pey Ni Chan, General Manager of CMIC (Beijing) Co., Ltd. “We are committed to be a trusted partner for our clients not only offering Chinese patients access to new treatments, but also to be a reliable navigator to Chinese companies looking for business expansions into Japan and other growing markets in the Asia-Pacific, as well as in the United States.”

Regarding the merger scheme, CPS will be integrated into CB. The CB business will continue as the operating company, and CMIC group will further expand its operations in China to speed up patient access to new treatments.

<Overview of the Operating Companies (tentative)>

(1)Trade name CMIC (Beijing) Co., Ltd.
(2) Main business Clinical CRO services in China
(3) Shareholders and holding ratios Wholly-owned subsidiary
(4)Accounting term December 31
(5)Location Twin Towers East Building, Unit 1702
B-12 Jianguomenwai Avenue, Chaoyang District, Beijing, China 100022
(6)Representative Pey Ni Chan, General Manager


To learn more about CMIC’s clinical CRO services in Asia Pacific, please click here


<About CMIC Group>

CMIC stands for Current Medical Information Center. CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.

For more information, visit CMIC Group’s website:

【Contact us】


TEL: +81-3-6779-8200 E-mail: